Interpreting the Results

Predict both clinical risk and tumor aggressiveness

Oncotype DX GPS is proven to be an independent predictor of both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3, 3+4 and 4+3.1-4

GPS animation

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report, and view sample reports .

 

View Sample Reports

Download Favorable Intermediate NCCN risk and a GPS result of 12 Report
Download Favorable Intermediate NCCN risk and a GPS result of 12 Report

Download Unfavorable Intermediate NCCN risk and a GPS result of 20
Download Unfavorable Intermediate NCCN risk and a GPS result of 20 Report

Download Low NCCN risk and a GPS result of 10
Download Low NCCN risk and a GPS result of 10 Report

Download Low NCCN risk and a GPS result of 58
Download Low NCCN risk and a GPS result of 58 Report

 

How do you use the GPS™ report? The value of the GPS™ assay.

Dr. Scott Sellinger (Advanced Urology Institute) describes how and why he uses the GPS report in his practice.

Learn about Adverse Pathology

 

Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Exact Sciences Laboratory. You can access the results through the online physician portal or receive the report by fax.

Start Report Guide
Start Report Guide
Page 1 2
Download PDF
Start Report Guide
Start Report Guide
Page 1 2

MORE TOPICS:

  • Explaining test results to patients
  • Interpreting the results
  • Publications
    • REFERENCES

    1. Van Den Eeden et al. Eur Urol. 2017.
    2. Klein et al. Eur Urol. 2014.
    3. Cullen et al. Eur Urol. 2014.
    4. Cullen et al. Urology. 2020.

    *Adverse pathology defined as Gleason ≥4+3 and/or pT3+.
    National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

    Stay in Touch

    Have questions? We're here to help.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
    Making cancer care smarter.®
    X

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.